ClinicalTrials.gov
public full text
Public Domain
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
The purpose of this clinical phase I/II study was to investigate the safety and tolerability of satoreotide tetraxetan (177Lu-IPN01072, formerly known as 177Lu-OPS201) used for the treatment of patients with neuroendocrine tumors (NETs). The secondary objectives of this study were the assessment of biodistribution, dosimetry and preliminary efficacy of satoreotide tetraxetan.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy#812056
- ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours#1005334
- Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma#838900
- Patients With High-grade Pancreatic Neuroendocrine Tumors#852133
- First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors#912759
Record · ID 1125437
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive